Athersys Newswire

Athersys Newswire

Comprehensive Real-Time News Feed for Athersys.

Results 1 - 20 of 131 in Athersys

  1. Athersys (ATHX) Downgraded by Zacks Investment Research to "Hold"Read the original story w/Photo

    Yesterday | IntersportsWire

    According to Zacks, "Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The company's lead product candidate, ATHX-105, is an oral, selective 5HT2c receptor agonist in Phase I clinical trials for the treatment of obesity.

    Comment?

  2. Athersys (ATHX) Cut to Hold at Zacks Investment ResearchRead the original story w/Photo

    Wednesday | AmericanBankingNews.com

    According to Zacks, "Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The company's lead product candidate, ATHX-105, is an oral, selective 5HT2c receptor agonist in Phase I clinical trials for the treatment of obesity.

    Comment?

  3. Athersys (ATHX) Upgraded to Buy by Zacks Investment ResearchRead the original story w/Photo

    Wednesday | IntersportsWire

    They currently have $2.25 price objective on the biopharmaceutical company's stock. According to Zacks, "Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life.

    Comment?

  4. Athersys (ATHX) Upgraded to "Buy" at Zacks Investment ResearchRead the original story w/Photo

    Tuesday | AmericanBankingNews.com

    ... 's price target would indicate a potential upside of 14.21% from the company's previous close. According to Zacks, "Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend ...

    Comment?

  5. Athersys to Host First Quarter Financial Results CallRead the original story

    Thursday Apr 12 | Customer Interaction Solutions

    CLEVELAND, April 12, 2018 -- Athersys, Inc. will release its first quarter 2018 financial results at approximately 4:00 PM Eastern Time on Thursday, May 10, 2018, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results. Gil Van Bokkelen, Chairman and Chief Executive Officer, and William Lehmann, President and Chief Operating Officer, will host the call as follows: A replay will be available for on-demand listening shortly after the completion of the call until 11:59 PM Eastern Time on May 24, 2018 at the aforementioned URL, or by dialing 585-8367 or 859-2056 in the U.S. and Canada, or from abroad 537-3406, and entering access code 1189915.

    Comment?

  6. Athersys (ATHX) Cut to Hold at Zacks Investment ResearchRead the original story w/Photo

    Monday Apr 9 | AmericanBankingNews.com

    According to Zacks, "Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The company's lead product candidate, ATHX-105, is an oral, selective 5HT2c receptor agonist in Phase I clinical trials for the treatment of obesity.

    Comment?

  7. ValuEngine Downgrades Athersys (ATHX) to SellRead the original story w/Photo

    Sunday Apr 8 | AmericanBankingNews.com

    Several other equities analysts also recently issued reports on the stock. Zacks Investment Research downgraded shares of Athersys from a "buy" rating to a "hold" rating in a report on Thursday, August 31st.

    Comment?

  8. Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Athersys (ATHX) Share PriceRead the original story w/Photo

    Sunday Apr 8 | IntersportsWire

    News stories about Athersys have been trending somewhat positive recently, according to Accern Sentiment. The research group scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time.

    Comment?

  9. Somewhat Favorable News Coverage Somewhat Unlikely to Impact Athersys (ATHX) Stock PriceRead the original story w/Photo

    Tuesday Apr 3 | Daily Political

    News articles about Athersys have trended somewhat positive this week, according to Accern Sentiment. Accern rates the sentiment of press coverage by monitoring more than twenty million blog and news sources in real-time.

    Comment?

  10. Holowesko Partners LTD Lifted By $675,000 Its China Mobile Limited...Read the original story

    Sunday Mar 25 | Hill Country Times

    Holowesko Partners LTD Lifted By $675,000 Its China Mobile Limited Holding; Athersys, Inc. Had 2 Bullish Analysts Among 2 analysts covering Athersys Inc , 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive.

    Comment?

  11. Valley National Bancorp (VLY) EPS Estimated At $0.20; ATHERSYS Has 1.12 SentimentRead the original story w/Photo

    Saturday Mar 24 | Hill Country Times

    Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. The company has market cap of $236.56 million.

    Comment?

  12. Athersys (ATHX) Rating Increased to Hold at ValuEngineRead the original story w/Photo

    Friday Mar 23 | Daily Political

    Separately, Maxim Group reiterated a "buy" rating and set a $6.00 target price on shares of Athersys in a research report on Tuesday, March 13th. Shares of Athersys stock opened at $1.88 on Thursday.

    Comment?

  13. Athersys (ATHX) Upgraded to Hold at ValuEngineRead the original story w/Photo

    Friday Mar 23 | AmericanBankingNews.com

    Separately, Maxim Group reissued a "buy" rating and issued a $6.00 price objective on shares of Athersys in a research report on Tuesday, March 13th. Athersys stock traded down $0.06 during trading hours on Thursday, hitting $1.88.

    Comment?

  14. Athersys (ATHX) Upgraded by ValuEngine to HoldRead the original story w/Photo

    Friday Mar 23 | IntersportsWire

    Separately, Maxim Group restated a buy rating and issued a $6.00 price target on shares of Athersys in a research report on Tuesday, March 13th. Shares of Athersys stock traded up $0.01 during mid-day trading on Thursday, reaching $1.95.

    Comment?

  15. Athersys Reports Financial Results for Fourth Quarter, Full Year 2017Read the original story

    Mar 13, 2018 | Customer Interaction Solutions

    ... in the United States and Europe, as well as other important activities," commented Dr. Gil Van Bokkelen, CEO of Athersys. Announced today plans to significantly expand our existing HEALIOS K.K. ("Healios") collaboration, including a $21.1 million ...

    Comment?

  16. Market Movers Today: Proteostasis Therapeutics Inc (PTI), BlueLinx...Read the original story w/Photo

    Mar 13, 2018 | Insider Monkey

    ... wholesale distributor, will enhance BlueLinx's product offerings, capabilities, and geographic reach. Athersys, Inc. (NASDAQ:ATHX) (Benzinga) Athersys, Inc. rose 14.7 percent to $1.79 after biotechnology company that focuses on regenerative medicine ...

    Comment?

  17. Pro's 5 Stock To Watch TodayRead the original story

    Mar 13, 2018 | Benzinga

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Athersys, Inc. stock gained more than 25 percent early Tuesday morning after biotechnology company that focuses on regenerative medicine received an equity investment.

    Comment?

  18. Athersys and HEALIOS Announce Binding Letter of Intent to Expand MultiStem CollaborationRead the original story

    Mar 13, 2018 | Customer Interaction Solutions

    Athersys, Inc. and HEALIOS K.K. announced today their intent to significantly expand their existing development and commercialization collaboration. As part of this expansion, Healios is making an approximate $21 million equity investment at $1.76 per share, will deposit $10 million into escrow, and has entered into a letter of intent with Athersys to expand Healios' license to develop MultiStemA products for indications to include acute respiratory distress syndrome , trauma in Japan and the use of MultiStem products in conjunction with organ bud technology and certain ophthalmological indications globally.

    Comment?

  19. Athersys and Healios Announce Binding Letter of Intent to Expand MultiStem CollaborationRead the original story w/Photo

    Mar 12, 2018 | GlobeNewswire

    Athersys, Inc. and HEALIOS K.K. announced today their intent to significantly expand their existing development and commercialization collaboration. As part of this expansion, Healios is making an approximate $21 million equity investment at $1.76 per share, will deposit $10 million into escrow, and has entered into a letter of intent with Athersys to expand Healios' license to develop MultiStemA products for indications to include acute respiratory distress syndrome , trauma in Japan and the use of MultiStem products in conjunction with organ bud technology and certain ophthalmological indications globally.

    Comment?

  20. Athersys (ATHX) Trading -3.7% HigherRead the original story w/Photo

    Mar 10, 2018 | The Breeze

    Athersys, Inc. traded up 3.7% on Thursday . The company traded as high as $1.65 and last traded at $1.55.

    Comment?